NCT05665244 Laryngeal Cryotherapy for Refractory Neurogenic Cough
| NCT ID | NCT05665244 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Texas Southwestern Medical Center |
| Condition | Upper-Airway Cough Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 28 participants |
| Start Date | 2022-12-26 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 28 participants in total. It began in 2022-12-26 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the safety and efficacy of upper aerodigestive tract cryotherapy treatment in patients with refractory neurogenic cough in a prospective pilot study with a validated patient reported outcome measure
Eligibility Criteria
Inclusion Criteria: * Adult patients 18 years or older with diagnosis of neurogenic cough * Neurogenic cough is a diagnosis of exclusion applied to persistent cough (8 weeks or longer) * Negative workup for other causes, including sinonasal allergies/chronic sinusitis, cough-variant asthma, and GERD * Patient willing to participate in a clinical trial Exclusion Criteria: * Uncontrolled reflux (scoring on Reflux Symptom index of 13 or higher) * Vocal fold abnormalities or impairment * History of asthma or other underlying lung condition not adequately treated or controlled * Uncontrolled Allergic Rhinitis (Total Nasal Symptom Score \>6, which would indicate moderate disease32) * Reported symptom of postnasal drip * Current smoker * Current neuromodulator medication use * Patient unwilling to participate in clinical trial or sign an informed consent * End stage medical disease with poor life expectancy * Medical instability deemed by the investigators as a contraindication for enrollment * Abnormal Chest X-ray * Abnormal pulmonary function testing (PFTs) * Positive local allergy panel (combined RAST testing)
Contact & Investigator
Shumon Dhar, MD
PRINCIPAL INVESTIGATOR
University of Texas Southwestern Medical Center
Frequently Asked Questions
Who can join the NCT05665244 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Upper-Airway Cough Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05665244 currently recruiting?
Yes, NCT05665244 is actively recruiting participants. Contact the research team at Shumon.Dhar@UTSouthwestern.edu for enrollment information.
Where is the NCT05665244 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT05665244 clinical trial?
NCT05665244 is sponsored by University of Texas Southwestern Medical Center. The principal investigator is Shumon Dhar, MD at University of Texas Southwestern Medical Center. The trial plans to enroll 28 participants.